HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Michelle Melisko Selected Research

Breast Neoplasms (Breast Cancer)

5/202468Ga-FAP-2286 PET of Solid Tumors: Biodistribution, Dosimetry, and Comparison with 18F-FDG.
12/2023Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery.
10/2023Tamoxifen or aromatase inhibitors with ovarian function suppression in pre-menopausal stage I-III lobular breast cancer.
10/2023Crofelemer for the Management of Neratinib-Associated Diarrhea in Patients With HER2+ Early-Stage Breast Cancer.
1/2023A Pilot Study of Associations Between the Occurrence of Palpitations and Cytokine Gene Variations in Women Prior to Breast Cancer Surgery.
1/2023Polymorphisms in Cytokine Receptor and Regulator Genes are Associated with Levels of Exercise in Women Prior to Breast Cancer Surgery.
12/2022Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.
11/2022The 21-Gene Recurrence Score in Clinically High-Risk Lobular and Ductal Breast Cancer: A National Cancer Database Study.
10/2022GLORIA: phase III, open-label study of adagloxad simolenin/OBI-821 in patients with high-risk triple-negative breast cancer.
12/2021The incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database Study.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Michelle Melisko Research Topics

Disease

29Breast Neoplasms (Breast Cancer)
05/2024 - 04/2005
19Neoplasms (Cancer)
05/2024 - 09/2007
8Fatigue
01/2022 - 06/2014
5Triple Negative Breast Neoplasms
12/2022 - 08/2014
4Pathologic Complete Response
12/2022 - 01/2020
4Lung Neoplasms (Lung Cancer)
12/2017 - 08/2015
3Lobular Carcinoma
10/2023 - 12/2021
3Peripheral Nervous System Diseases (PNS Diseases)
10/2019 - 04/2005
3Pain (Aches)
02/2016 - 04/2005
2Diarrhea
10/2023 - 05/2021
2Ductal Carcinoma
11/2022 - 12/2021
2Neutropenia
05/2021 - 06/2013
2Cardiotoxicity
10/2018 - 10/2018
2Lymphedema (Milroy Disease)
10/2018 - 09/2014
1Colonic Neoplasms (Colon Cancer)
05/2024
1Cholangiocarcinoma
05/2024
1Adenocarcinoma
05/2024
1Head and Neck Neoplasms (Head and Neck Cancer)
05/2024
1Hepatocellular Carcinoma (Hepatoma)
05/2024
1Neurodegenerative Diseases (Neurodegenerative Disease)
04/2024
1Back Pain (Backache)
01/2023
1Hypertension (High Blood Pressure)
01/2023
1Neoplasm Metastasis (Metastasis)
01/2023
1Arachnoiditis
01/2023
1Hyperglycemia
10/2021
1Circulating Neoplastic Cells
09/2021
1Leukopenia
05/2021
1Exanthema (Rash)
05/2021
1Nausea
01/2020
1Hypertrophic Cardiomyopathy (Hypertrophic Obstructive Cardiomyopathy)
10/2018
1Pulmonary Arterial Hypertension
10/2018
1Residual Neoplasm
07/2016
1Syndrome (Syndromes)
02/2016
1Inflammation (Inflammations)
01/2016
1Brain Neoplasms (Brain Tumor)
08/2014

Drug/Important Bio-Agent (IBA)

9Hormones (Hormone)IBA
01/2024 - 07/2016
7Trastuzumab (Herceptin)FDA Link
12/2023 - 07/2015
6Paclitaxel (Taxol)FDA LinkGeneric
12/2023 - 06/2013
3CytokinesIBA
01/2023 - 02/2014
3Cyclophosphamide (Cytoxan)FDA LinkGeneric
11/2021 - 05/2011
3Doxorubicin (Adriamycin)FDA LinkGeneric
11/2021 - 05/2011
2Biomarkers (Surrogate Marker)IBA
12/2023 - 10/2021
2neratinibIBA
10/2023 - 07/2016
2ErbB Receptors (EGF Receptor)IBA
01/2023 - 06/2013
2olaparibIBA
12/2021 - 12/2020
2Poly(ADP-ribose) Polymerase InhibitorsIBA
12/2021 - 12/2020
2human ERBB2 proteinIBA
12/2020 - 05/2011
2VaccinesIBA
01/2019 - 08/2014
2Bevacizumab (Avastin)FDA Link
06/2013 - 05/2011
1Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link
05/2024
1Proteins (Proteins, Gene)FDA Link
05/2024
1trebananibIBA
12/2023
1Selective Estrogen Receptor Modulators (SERM)IBA
10/2023
1TamoxifenFDA LinkGeneric
10/2023
1Aromatase InhibitorsIBA
10/2023
1crofelemer (SP-303)IBA
10/2023
1Interleukin-10 (Interleukin 10)IBA
01/2023
1Cytokine Receptors (Cytokine Receptor)IBA
01/2023
1Interleukin-13IBA
01/2023
1InterleukinsIBA
01/2023
1STA 9090IBA
12/2022
1Immunoglobulin G (IgG)IBA
10/2022
1Immunoglobulin M (IgM)IBA
10/2022
1Conjugate VaccinesIBA
10/2022
1Globo-HIBA
10/2022
1GlycosphingolipidsIBA
10/2022
1durvalumabIBA
12/2021
1Immune Checkpoint InhibitorsIBA
12/2021
1pertuzumabIBA
11/2021
1Ado-Trastuzumab EmtansineIBA
11/2021
1Hemoglobins (Hemoglobin)IBA
10/2021
1Metformin (Glucophage)FDA LinkGeneric
10/2021
1ganitumabIBA
10/2021
1Zoledronic Acid (Zometa)FDA Link
09/2021
1Capecitabine (Xeloda)FDA Link
05/2021
1glembatumumab vedotinIBA
05/2021
1Immunoconjugates (Immunoconjugate)IBA
05/2021
1Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA
12/2020
1pembrolizumabIBA
01/2020
1AntiemeticsIBA
01/2020
1HER2 peptide (369-377)IBA
01/2019
1Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA
01/2019
1Amyloid (Amyloid Fibrils)IBA
10/2018
1AnthracyclinesIBA
10/2018
1Neurotransmitter Agents (Neurotransmitter)IBA
01/2016
1Lapatinib (GW572016)FDA Link
07/2015
1Drug CombinationsIBA
07/2015
1Tyrosine Kinase InhibitorsIBA
07/2015
1Irinotecan (Camptosar)FDA LinkGeneric
08/2014
1Reactive Oxygen Species (Oxygen Radicals)IBA
08/2014
1iniparibIBA
08/2014
1Topoisomerase I InhibitorsIBA
08/2014

Therapy/Procedure

20Drug Therapy (Chemotherapy)
04/2024 - 04/2005
14Therapeutics
01/2024 - 04/2005
6Neoadjuvant Therapy
01/2023 - 07/2016
2Aftercare (After-Treatment)
06/2014 - 08/2012
1Investigational Therapies (Experimental Therapy)
12/2023
1Adjuvant Chemotherapy
01/2020
1Resistance Training
09/2014
1Ostomy
09/2014